PubMed Health⌕ Search

PubMed · 14667311

Cosmic microwave background snapshots: pre-WMAP and post-WMAP.

Abstract

We highlight the remarkable evolution in the cosmic microwave background (CMB) power spectrum C(l) as a function of multipole l over the past few years, and in the cosmological parameters for minimal inflation models derived from it: from anisotropy results before 2000; in 2000 and 2001 from Boomerang, Maxima and the Degree Angular Scale Interferometer (DASI), extending l to approximately 1000; and in 2002 from the Cosmic Background Imager (CBI), Very Small Array (VSA), ARCHEOPS and Arcminute Cosmology Bolometer Array Receiver (ACBAR), extending l to approximately 3000, with more from Boomerang and DASI as well. Pre-WMAP (pre-Wilkinson Microwave Anisotropy Probe) optimal band powers are in good agreement with each other and with the exquisite one-year WMAP results, unveiled in February 2003, which now dominate the l less, similar 600 bands. These CMB experiments significantly increased the case for accelerated expansion in the early Universe (the inflationary paradigm) and at the current epoch (dark energy dominance) when they were combined with "prior" probabilities on the parameters. The minimal inflation parameter set, [omega(b), omega(cdm), Omega(tot), Omega(Lambda), n(s), tau(C), sigma(8)], is applied in the same way to the evolving data. C(l) database and Monte Carlo Markov Chain (MCMC) methods are shown to give similar values, which are highly stable over time and for different prior choices, with the increasing precision best characterized by decreasing errors on uncorrelated "parameter eigenmodes". Priors applied range from weak ones to stronger constraints from the expansion rate (HST-h), from cosmic acceleration from supernovae (SN1) and from galaxy clustering, gravitational lensing and local cluster abundance (LSS). After marginalizing over the other cosmic and experimental variables for the weak + LSS prior, the pre-WMAP data of January 2003 compared with the post-WMAP data of March 2003 give Omega(tot) = 1.03(-0.04)(+0.05) compared with 1.02(-0.03)(+0.04), consistent with (non-Baroque) inflation theory. Adding the flat Omega(tot) = 1 prior, we find a nearly scale-invariant spectrum, n(s) = 0.95(-0.04)(+0.07) compared with 0.97(-0.02)(+0.02). The evidence for a logarithmic variation of the spectral tilt is less than or approximately 2sigma. The densities are for: baryons, omega(b) identical with Omega(b)h(2) = 0.0217(-0.002)(+0.002) (compared with 0.0228(-0.001)(+0.001)), near the Big Bang nucleosynthesis (BBN) estimate of 0.0214 +/- 0.002; CDM, omega(cdm) = Omega(cdm)h(2) = 0.126(-0.012)(+0.012) (compared with 0.121(-0.010)(+0.010)); the substantial dark (unclustered) energy, Omega(Lambda) approximately 0.66(-0.09)(+0.07) (compared with 0.70(-0.05)(+0.05)). The dark energy pressure-to-density ratio w(Q) is not well constrained by our weak + LSS prior, but adding SN1 gives w(Q) less than or approximately -0.7 for January 2003 and March 2003, consistent with the w(Q) = -1 cosmological constant case. We find sigma(8) = 0.89(-0.07)(+0.06) (compared with 0.86(-0.04)(+0.04)), implying a sizable Sunyaev-Zel'dovich (SZ) effect from clusters and groups; the high-l power found in the January 2003 data suggest sigma(8) approximately 0.94(-0.16)(+0.08) is needed to be SZ-compatible.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Richard Bond, Carlo Contaldi, Dmitry Pogosyan. 2003-11-15. Cosmic microwave background snapshots: pre-WMAP and post-WMAP.. https://doi.org/10.1098/rsta.2003.1295

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗